Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

Nexstim takes on new money man

This article was originally published in Clinica

  • News

Executive Summary

Nexstim, the Finnish specialist in navigated brain stimulation, has appointed Mikko Karvinen as chief financial officer, effective 18 August. This is Mr Karvinen’s first foray in the healthcare sector: he was previously CFO at Nordic IT solution provider Innofactor and before that, at SSH Communications Security. His role at Nexstim was formerly held by Janne Huhtala, who was promoted to the role of CEO in January 2013. Privately-held Nexstim is backed by Capricorn Health-tech Fund; Finnish Industry Investment; HealthCap; Ilmarinen; Life Sciences Partners; Lundbeckfond Ventures; and SITRA. The company’s NBT system is CE-marked and US FDA-cleared for brain mapping prior to neurosurgery and is currently being trialled for stroke therapy.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

Rise In Class I Device Recalls A ‘Grave Concern,’ Says FDA’s Anne Reid

Discreet Gait Freezing Solution Brings Therapy With The Tap Of An Apple Watch

Shuren Says CDRH Is ‘Turning The Ship Around’ As Operations Return To Normal

EU: Good News For IVDs And For Future Transparency Of Medtech Compliance

See All
UsernamePublicRestriction

Register

MT101840

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By